Evidence map›Paper›PMID 39615677›Full record

ArticleThe Journal of biological chemistry2025

The serine protease DPP9 and the redox sensor KEAP1 form a mutually inhibitory complex.

Lydia P Tsamouri, Jeffrey C Hsiao, Daniel A Bachovchin

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lydia P TsamouriPharmacology Program of the Weill Cornell Graduate School of Medical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jeffrey C HsiaoPharmacology Program of the Weill Cornell Graduate School of Medical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Daniel A BachovchinPharmacology Program of the Weill Cornell Graduate School of Medical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Electronic address: bachovcd@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Characterizing the Mechanism of DPP8/9 Inhibitor-Induced PyroptosisR01AI137168 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Bachovchin · 2018 to 2026
$4.3M
Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid LeukemiaR01CA266478 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Bachovchin · 2022 to 2026
$3.1M
Redox control of the NLRP1 inflammasomeR01AI163170 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI BACHOVCHIN, DANIEL · 2021 to 2025
$2.6M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA266478NIAID NIH HHS R01 AI137168NIAID NIH HHS R01 AI163170
6 · The paper itself

Abstract

Synthetic inhibitors of the serine protease DPP9 activate the related NLRP1 and CARD8 inflammasomes and stimulate powerful innate immune responses. Thus, it seems plausible that a biomolecule similarly inhibits DPP9 and triggers inflammasome activation during infection, but one has not yet been discovered. Here, we wanted to identify and characterize DPP9-binding proteins to potentially uncover physiologically relevant mechanisms that control DPP9's activity. Notably, we found that the redox sensor protein KEAP1 binds to DPP9 in an inactive conformation and stabilizes this non-native fold. At the same time, this inactive form of DPP9 reciprocally inhibits the ability of KEAP1 to bind to and degrade the transcription factor NRF2, thereby inducing an antioxidant response. Although we discovered several experimental conditions, for example new protein expression and chemical denaturation, that force DPP9 out of its folded dimeric state and into a KEAP1-binding state, the key danger-related stimulus that causes this critical DPP9 conformational change is not yet known. Regardless, our data now reveal that an endogenous DPP9 inhibition mechanism does in fact exist, and moreover that DPP9, like the other NLRP1 regulator thioredoxin-1, is directly coupled to the intracellular redox potential. Overall, we expect this work will provide the foundation to discover additional biomolecules that regulate DPP9's activity, the DPP9-KEAP1 interaction, the intracellular redox environment, and the NLRP1 and CARD8 inflammasomes.

Indexed as

Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesKelch-Like ECH-Associated Protein 1HEK293 CellsHumansInflammasomesNF-E2-Related Factor 2Oxidation-ReductionProtein BindingDipeptidyl-Peptidases and Tripeptidyl-PeptidasesDPP9 protein, humanInflammasomesKEAP1 protein, humanKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2CARD8DPP9inflammasomeinhibitionKEAP1NLRP1NRF2proteaseredox

Identifiers

PMID39615677
PMCPMC11773481

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.